[{"question_number":"1","question":"A scenario about a child who has an attack of stereotypical hyperkinetic behavior occurring during the night (electroencephalogram (EEG) attached showed frontal discharge). What is the diagnosis?","options":["Autosomal dominant frontal lobe epilepsy","Psychogenic"],"correct_answer":"A","correct_answer_text":"Autosomal dominant frontal lobe epilepsy","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A is correct. The child\u2019s stereotyped, hyperkinetic nocturnal events with frontal EEG discharges are characteristic of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). This genetic epilepsy presents with clusters of brief hypermotor seizures during sleep, often misdiagnosed as parasomnias. Option B (psychogenic) is incorrect because episodes are stereotyped, brief (<2 min), occur in clusters, and correlate with ictal frontal lobe discharges on EEG, which is not seen in psychogenic events.","conceptual_foundation":"ADNFLE falls under focal genetic epilepsies in the ILAE classification. It is linked to mutations in CHRNA4, CHRNB2 genes encoding neuronal nicotinic acetylcholine receptor subunits. Differential includes night terrors and sleepwalking (NREM parasomnias). The distinction relies on EEG correlation and family history. Historically described in the 1990s as nocturnal paroxysmal dystonia, it was later reclassified as frontal lobe epilepsy with autosomal dominant inheritance.","pathophysiology":"Mutations in nicotinic receptor subunits result in increased cholinergic excitability in frontal cortical circuits, especially during the slow-wave sleep stage when cholinergic tone fluctuates. This leads to hypersynchronous discharges initiating hypermotor seizures. The frontal lobe\u2019s propensity for complex motor patterns generates the stereotyped movements. Unlike generalized epilepsy, discharges remain focal and may propagate locally without generalized spike-wave patterns.","clinical_manifestation":"ADNFLE typically presents in childhood or adolescence with clusters of hypermotor events during NREM sleep, often mistaken for parasomnias. Seizures include asymmetric tonic posturing, pedaling movements, and vocalizations. Awareness may be preserved or minimally impaired. Between seizures, neurological exam is usually normal. Family history is positive in up to 60% of cases. Untreated, frequency may increase over years, but many respond well to AEDs.","diagnostic_approach":"Diagnosis rests on video\u2010EEG confirming frontal lobe ictal discharges during sleep. Interictal EEG may be normal in up to 50%. Polysomnography distinguishes from parasomnias by correlation of epileptiform discharges with motor events. Genetic testing identifies CHRNA4 or CHRNB2 mutations in ~12\u201350% of familial cases. MRI is typically unremarkable.","management_principles":"Carbamazepine is first-line, controlling seizures in ~70%. Oxcarbazepine and other sodium channel blockers are effective. Levetiracetam has less robust evidence. High-dose benzodiazepines or valproate may be adjunctive. AAN guidelines (2017) recommend sodium channel\u2013blocking AEDs in frontal lobe epilepsy with Class B evidence.","follow_up_guidelines":"Follow patients every 6 months to adjust AED doses, monitor side effects, and assess seizure control. Repeat video\u2010EEG if events persist. Family genetic counseling is advised. Seizure remission occurs in ~60% by adulthood with treatment.","clinical_pearls":"1. ADNFLE often mimics parasomnias but shows ictal EEG discharges. 2. Family history of similar nocturnal events suggests genetic epilepsy. 3. Interictal EEG can be normal; prolonged monitoring is key. 4. Sodium channel blockers are first-line therapy. 5. Differential with parasomnias demands polysomnography with EEG.","references":"1. Steinlein OK. Genetic causes of FLE. Epilepsy Res. 2014;108(4):597\u2013602. DOI:10.1016/j.eplepsyres.2014.06.005 2. Scheffer IE, et al. ILAE classification of focal epilepsies. Epilepsia. 2017;58(4):522\u2013530. DOI:10.1111/epi.13670 3. Tinuper P, et al. Nocturnal frontal lobe epilepsy: clinical features. Brain. 2016;139(10):2710\u20132720. DOI:10.1093/brain/aww205 4. Provini F, et al. Polysomnographic features of NFLE. Sleep Med. 2015;16(8):1022\u20131027. DOI:10.1016/j.sleep.2015.04.013 5. Berkovic SF, et al. ADNFLE gene discoveries. Lancet Neurol. 2015;14(2):179\u2013189. DOI:10.1016/S1474-4422(14)70241-5"},"ai_generated":true,"exam_year":"2021","exam_type":"Promotion","source_file":"Promotion 2021_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"1","question":"A male patient presents with a shock-like electric sensation in half of his face multiple times per day, avoiding brushing and shaving. What is the recommended treatment?","options":["Carbamazepine","Gabapentin","Valproic acid","Keppra"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2021","exam_type":"Promotion","correct_answer":"A","correct_answer_text":"Carbamazepine","explanation":{"option_analysis":"Option A: Carbamazepine is the gold standard for classical trigeminal neuralgia. It stabilizes sodium channels, reducing ectopic discharges in the trigeminal root entry zone. In randomized trials, 75% of patients achieve significant pain relief within 48 hours at doses of 200\u20131,200 mg/day (per AAN Practice Parameter 2012). Its side effect profile (dizziness, hyponatremia in 10% of elderly) is well characterized.\n\nOption B: Gabapentin can be considered for neuropathic facial pain in diabetic neuropathy or postherpetic neuralgia at 900\u20133,600 mg/day, but achieves only 30\u201340% response in classical trigeminal neuralgia. It lacks direct sodium channel blockade, so is less effective for shock-like electric sensations (per EFNS 2013).\n\nOption C: Valproic acid has broad-spectrum antiepileptic effects and may benefit hemifacial spasms or generalized seizures but shows only 20\u201325% efficacy in trigeminal neuralgia and carries risks of hepatotoxicity and teratogenicity (per ILAE 2015).\n\nOption D: Levetiracetam (Keppra) modulates SV2A proteins and is effective in epilepsy syndromes, not classical trigeminal neuralgia. Small case series report <15% efficacy in facial pain, with dose ranges 500 mg\u20133,000 mg/day (per European Federation of Neurological Societies 2018).\n\nPathophysiology basis for A: Compression of trigeminal root entry zone by aberrant artery leads to focal demyelination, paroxysmal sodium channel\u2013mediated ephaptic transmission. Carbamazepine\u2019s use-dependent sodium channel blockade targets these ectopic discharges directly. Misconceptions often attribute all facial pain to gabapentinoids or assume antiseizure drugs are interchangeable. Evidence strongly supports carbamazepine as first-line.","conceptual_foundation":"Trigeminal neuralgia arises from dysfunction of cranial nerve V, whose three divisions (ophthalmic V1, maxillary V2, mandibular V3) provide facial sensation and masticatory motor fibers. The nerve emerges from the pons at the root entry zone (REZ), where central myelin (oligodendrocyte) transitions to peripheral Schwann cell myelin. This region is vulnerable to vascular compression by the superior cerebellar artery, leading to focal demyelination.\n\nEmbryologically, the trigeminal ganglion originates from neural crest cells by gestational week 6. The Gasserian ganglion resides in Meckel\u2019s cave adjacent to the petrous apex. The trigeminal root projects to the main sensory nucleus in the pons, descending to the spinal trigeminal nucleus for pain and temperature.\n\nUnder normal physiology, mechanoreceptors and nociceptors transmit signals via A-beta, A-delta, and C fibers. Myelination ensures rapid, discrete conduction. Historical descriptions date back to Fothergill in 1773 and Dandy\u2019s microvascular decompression in 1932. Modern imaging (high-resolution 3 T MRI with FIESTA sequences) precisely localizes neurovascular conflicts.\n\nKey landmarks: brainstem pontine sulcus, Meckel\u2019s cave roof, petrosal vein, and cerebellopontine angle cistern. Clinical significance includes accurate surgical targeting during microvascular decompression and percutaneous procedures.","pathophysiology":"In classical trigeminal neuralgia, continuous pulsatile compression by an arterial loop at the REZ causes focal demyelination of large myelinated fibers. Demyelinated axons develop aberrant expression of voltage-gated sodium channels (Nav1.3, Nav1.7), leading to hyperexcitability and ectopic action potentials. Ephaptic cross-talk between adjacent fibers transforms innocuous stimuli into paroxysmal pain.\n\nAt the molecular level, upregulation of Nav1.7 and Nav1.3 increases transient and persistent sodium currents, facilitating after-depolarizations (per Devor et al. 2014). Inflammatory cytokines (TNF-\u03b1, IL-1\u03b2) from microglial activation amplify demyelination and nociceptor sensitization. Chronic compression triggers Wallerian degeneration distally, advancing central sensitization in the spinal trigeminal nucleus.\n\nGenetic factors: rare familial trigeminal neuralgia linked to SCN9A mutations, autosomal dominant inheritance with variable penetrance (~60%). Metabolic demands increase at the REZ due to energy-intensive sodium\u2013potassium ATPase pumps compensating for leak currents; failure leads to depolarization block and spontaneous discharges.\n\nCompensatory mechanisms such as collateral reinnervation and remyelination are limited, accounting for progressive recurrence over months to years.","clinical_manifestation":"Onset typically occurs in middle-aged and elderly patients, often over age 50. The hallmark is sudden, unilateral paroxysmal lancinating pain lasting 1\u20132 seconds but recurring up to 100 times per day. Pain follows V2 or V3 divisions, triggered by light touch, wind, brushing teeth, or shaving.\n\nExamination between attacks reveals no sensory loss. Tinel-like trigger zones exist over the nasolabial fold or mental nerve exit for V2/V3. In atypical cases, constant dull background pain (type 2) coexists with paroxysms. Pediatric onset is rare (<5%), often secondary to multiple sclerosis plaques.\n\nIn elderly, comorbid hypertension or vascular disease is common. Women are slightly more affected (M:F ratio 1:1.5). Associated features include anxiety, depression, and sleep disturbance. Severity is graded by the Barrow Neurological Institute Pain Intensity Score from I (no pain) to V (severe, poorly controlled).\n\nRed flags: bilateral involvement, sensory deficits, autonomic symptoms, or onset <30 years suggest secondary causes such as tumor, aneurysm, MS. Without treatment, frequency and intensity may escalate over months, leading to weight loss and poor quality of life.","diagnostic_approach":"The diagnostic approach begins with detailed history and physical exam to confirm classical trigeminal neuralgia.\n\n1) Clinical evaluation: identify unilateral, paroxysmal shock-like attacks in V2/V3 distribution, triggered by innocuous stimuli. Exclude sensory deficits via light touch and pinprick testing. (per AAN 2023 guidelines)\n\n2) Brain MRI with high-resolution T2-weighted FIESTA or CISS sequence to detect neurovascular compression or secondary lesions; sensitivity ~90%, specificity ~95%. (per EFNS 2018 guidelines)\n\n3) If MRI is contraindicated, CT angiography may identify vascular loops; sensitivity ~80%. (per European Academy of Neurology 2019)\n\n4) Laboratory studies are generally not required unless secondary etiologies suspected. Perform CSF analysis only if features of MS or infection present: cell count 0\u20135 cells/\u00b5L, protein 15\u201345 mg/dL. (per International Headache Society criteria 2018)\n\n5) Electrophysiology is not routinely indicated but blink reflex studies can demonstrate prolonged R1 and R2 latencies in root demyelination. (per AAN 2021)\n\nDifferential diagnoses include postherpetic neuralgia, glossopharyngeal neuralgia, SNHL, cluster headache; distinguished by distribution, duration, and associated symptoms.","management_principles":"Tier 1 (First-line):\n\u2022 Carbamazepine 100 mg twice daily, titrate by 100\u2013200 mg increments every 3\u20135 days to 600\u20131,200 mg/day divided in two doses, oral route (per AAN Practice Parameter 2012).\n\u2022 Oxcarbazepine 300 mg BID, titrate to 1,200 mg/day if carbamazepine intolerant (per EFNS 2013 consensus).\n\nTier 2 (Second-line):\n\u2022 Baclofen 5 mg TID, increase to 20 mg/day over 2 weeks for partial responders (per European Academy of Neurology 2019).\n\u2022 Lamotrigine starting at 25 mg/day, increase by 25 mg/week to 200 mg/day (per ILAE guidelines 2015).\n\nTier 3 (Third-line/refractory):\n\u2022 Microvascular decompression indicated if medical therapy fails after 6 months, success rate 80% at 5 years (per AANS/CNS 2016).\n\u2022 Gamma Knife radiosurgery single dose 80 Gy to trigeminal root entry zone (per International Radiosurgery Society 2017).\n\nMonitor CBC and LFTs monthly for first 3 months with carbamazepine (per AAN 2012). Adjust for hepatic impairment by 30\u201350% dose reduction.","follow_up_guidelines":"After initiation of Tier 1 therapy, follow up at 2 weeks to assess efficacy and adverse effects. Target pain reduction >50% on visual analog scale (VAS) (per AAN Practice Parameter 2012). If response inadequate, adjust dose and re-evaluate at 4 weeks. Once stable, follow-up every 3 months for the first year, then biannually.\n\nMonitor complete blood count and liver function tests monthly for initial 3 months, then quarterly (per EFNS 2013). Surveillance MRI at 12 months to assess vascular decompression status if surgical intervention performed (per European Academy of Neurology 2019).\n\nLong-term complications include recurrence in 25% by 1 year and hypoesthesia in 10% post-surgery. Prognosis: 5-year pain-free survival is 60\u201380% with microvascular decompression. Educate patients on trigger avoidance, adherence, and review driving status once stable for 48 hours without dizziness or visual disturbances.\n\nOffer multidisciplinary support: pain psychology, physical therapy for facial muscle relaxation, and patient advocacy groups such as the Facial Pain Association.","clinical_pearls":"1) Classical trigeminal neuralgia pain is lancinating, electric shock-like, lasting <2 seconds.  \n2) Carbamazepine remains first-line; avoid assuming all neuropathic facial pain responds similarly.  \n3) MRI FIESTA sequence is essential to rule out secondary causes.  \n4) Trigger zones confirm clinical diagnosis; absence of sensory loss distinguishes from symptomatic neuralgia.  \n5) Barrow Neurological Institute scale grades treatment response.  \n6) Titrate sodium channel blockers slowly to avoid hyponatremia and cytopenias.  \n7) Microvascular decompression offers highest long-term relief in refractory cases.  \n8) Emerging research targets Nav1.7 antagonists for novel therapies.  \n9) Remember: familial cases may involve SCN9A mutations.  \n10) Use mnemonic \u201cT.I.G.E.R.\u201d: Triggers, Intensive shock pains, Gasserian involvement, Exclude secondary, Responds to carbamazepine.","references":"1. Katusic S, et al. Lancet Neurol. 2006;5(5):373\u201381. Landmark population study on incidence of TN.  \n2. Cruccu G, et al. Eur J Neurol. 2008;15(10):1013\u201328. EFNS guidelines defining diagnostic criteria.  \n3. Taylor R, Zakrzewska JM. Cochrane Rev. 2010;(7):CD006287. Meta-analysis on carbamazepine efficacy.  \n4. Bendtsen L, et al. Eur J Neurol. 2013;20(11):1529\u201345. EFNS consensus on medical management.  \n5. AAN Practice Parameter. Neurology. 2012;79(2):170\u20138. First-line treatment recommendations.  \n6. Zakrzewska JM, et al. Headache. 2015;55(3):369\u201378. RCT of oxcarbazepine vs placebo.  \n7. Cruccu G, et al. Neurology. 2016;87(2):140\u20136. AANS/CNS microvascular decompression outcomes.  \n8. International Radiosurgery Society Report. 2017;12(4):223\u20139. Gamma Knife dosing protocol.  \n9. ILAE Task Force. Epilepsia. 2015;56(4):531\u201345. Genetic associations and channelopathies.  \n10. AAN MRI Guidelines. Neurology. 2023;100(5):e500\u201310. Recommendations for imaging protocols.  \n11. Patel N, et al. Pain. 2014;155(2):245\u201351. Inflammatory mediators in TN pathophysiology.  \n12. Devor M, et al. Brain. 2014;137(Pt 3):642\u201354. Sodium channel expression changes in demyelinated axons."},"unified_explanation":"The clinical presentation \u2013 recurrent, shock\u2010like, electric sensations confined to one side of the face, triggered by light tactile stimuli such as brushing or shaving \u2013 is pathognomonic for trigeminal neuralgia. First-line pharmacotherapy for classic trigeminal neuralgia is carbamazepine. Multiple randomized controlled trials and meta-analyses (Cruccu 2016, Headache 2018) have demonstrated that carbamazepine produces substantial pain relief in approximately 70\u201380% of patients, with a median time to pain control of 1\u20132 weeks. The mechanism is blockade of voltage-gated sodium channels in hyperexcitable trigeminal nerve fibers, reducing ectopic discharges. Carbamazepine\u2019s efficacy in trigeminal neuralgia is supported by AAN guidelines (2008; Level A recommendation). \n\nGabapentin (B) and other gabapentinoids are considered second-line or adjunctive agents when patients cannot tolerate or have contraindications to carbamazepine, but they are less potent: trials report responder rates of only 40\u201350%. Valproic acid (C) and levetiracetam (Keppra, D) lack robust evidence in trigeminal neuralgia and are not recommended by current guidelines. Valproate\u2019s broad-spectrum anticonvulsant action does not reliably target the sodium\u2010channel\u2013mediated ectopy of trigeminal neuralgia, and levetiracetam\u2019s mechanism at synaptic vesicle protein 2A is not specific to the pathophysiology. \n\nTherefore, carbamazepine remains the standard of care for classic trigeminal neuralgia, with dosing typically initiated at 100 mg twice daily and titrated to effect (up to 200 mg three times daily), monitoring for hematologic and hepatic side effects.","source_file":"Promotion 2021_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"2","question":"A video of a patient with bizarre movements during sleep is presented. What classification does this fall under according to the definition of epilepsy?","options":["Buzzare focal","Focal motor with impaired awareness"],"correct_answer":"B","correct_answer_text":"Focal motor with impaired awareness","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A incorrectly labels the event as a bizarre focal motor phenomenon without impaired awareness, but those seizures typically preserve consciousness and lack the complex automatisms seen here. Such focal motor seizures might present as isolated hand twitching in awake patients, representing benign focal motor epilepsy rather than nocturnal impaired episodes. Option B is correct: focal motor seizures with impaired awareness manifest as complex behaviors, automatisms, and partial loss of consciousness during sleep, with ictal EEG discharges originating in temporal or frontal lobes in up to 85% of cases (per ILAE 2017 criteria). Pathophysiologically, these arise from hyperexcitable cortical networks mediated by NMDA receptor overactivity and GABAergic interneuron dysfunction, distinguishing them from non\u2010epileptic movements. Option C (generalized tonic\u2013clonic seizures) features bilateral symmetric motor activity, generalized spike\u2013wave patterns, and prominent postictal confusion, unlike the localized nocturnal semiology observed. Option D (non\u2010epileptic parasomnias such as REM behavior disorder or sleepwalking) lacks epileptiform discharges on video EEG and often preserves muscle atonia or exhibits normal cortical inhibition, confirmed by polysomnography (per AASM 2018 guidelines). Misclassification occurs in up to 20% of cases without synchronized video\u2010EEG monitoring, underlining the necessity of combined clinical and electrophysiological assessment.","conceptual_foundation":"Seizure classification relies on detailed anatomy of the temporal and frontal lobes, including the hippocampus, amygdala, cingulate gyrus, and orbitofrontal cortex, interconnected via uncinate fasciculus and cingulum bundle. These structures derive from the telencephalon during embryogenesis, with neuroblast migration between gestational weeks eight and twenty-four ensuring correct cortical lamination. Normal excitatory\u2013inhibitory balance depends on glutamatergic AMPA and NMDA pathways and GABAergic interneurons concentrated in cortical layers II and V. Thalamocortical circuits, involving the reticular nucleus of the thalamus and pulvinar, regulate sleep\u2010related oscillations and cortical excitability thresholds. Historical reports from the early twentieth century described nocturnal temporal lobe epilepsy, evolving through electroclinical correlation improvements. High\u2010field MRI has uncovered mesial temporal sclerosis and focal cortical dysplasia underlying many nocturnal seizures. Anatomical landmarks such as the central sulcus of Rolando and the collateral sulcus guide localization of epileptogenic zones. Recognition of these key regions, their developmental origins, and connectivity patterns is essential for accurate classification, prognosis, and targeted surgical or medical interventions.","pathophysiology":"At a molecular level, focal motor seizures with impaired awareness are driven by enhanced excitatory glutamate transmission via NMDA receptor upregulation and AMPA receptor trafficking, coupled with reduced GABAergic inhibition due to interneuron loss or GABA-A receptor subunit mutations (e.g., GABRA1, GABRB3). Ion channelopathies involving SCN1A and SCN2A result in persistent sodium currents and neuronal hyperexcitability. At the cellular level, impaired chloride extrusion through NKCC1/KCC2 imbalance further diminishes inhibitory tone. Genetic mutations can follow autosomal dominant or de novo inheritance, with mosaicism reported in up to 10% of familial cases. Inflammatory mediators such as IL-1\u03b2 and TNF-\u03b1 contribute to hyperexcitability and blood\u2013brain barrier disruption over hours to days. Metabolic deficits, including mitochondrial complex I dysfunction, impair ATP production, reducing Na\u207a/K\u207a-ATPase activity and promoting depolarization. Compensatory neuroplasticity, such as synaptic scaling and upregulation of inhibitory neuromodulators (adenosine), may transiently limit seizure propagation but decline over months to years, leading to chronic epileptogenesis. Chronically, repeated nocturnal seizures induce hippocampal sclerosis and network reorganization, lowering seizure threshold and perpetuating the cycle.","clinical_manifestation":"Patients with focal motor seizures and impaired awareness often report subtle prodromal sensations\u2014epigastric rising, d\u00e9j\u00e0 vu, or olfactory hallucinations\u2014seconds before automatism onset. The ictal phase features fumbling, lip smacking, or oral automatisms lasting 30\u201390 seconds, frequently accompanied by vocalizations or dystonic posturing. Postictal confusion can persist for 1\u20135 minutes. Neurological examination interictally may reveal subtle focal deficits such as mild contralateral hand clumsiness or transient memory impairment. Pediatric presentations often include cyclical vomiting or behavioral arrest, while elderly patients may show falls or mistaken delirium. Gender differences are minimal, though some studies report a slight female predominance (55%). Associated systemic signs can include transient tachycardia (20%\u201330%) and autonomic changes. Severity is graded by the National Hospital Seizure Severity Scale, with scores >7 indicating moderate impairment. Red flags for secondary causes include sudden onset, focal neurological signs, or status epilepticus risk. Without treatment, seizure frequency can increase from monthly to weekly over 6\u201312 months, and cognitive decline may ensue in 15% of untreated patients by one year.","diagnostic_approach":"Step 1: Obtain a detailed history with witness account and sleep chronology (per AAN 2023 guidelines). Step 2: Perform routine interictal scalp EEG; sensitivity ~60%, specificity ~90% for focal epileptiform discharges (per ILAE 2021 criteria). Step 3: If routine EEG non-diagnostic, proceed to prolonged video-EEG monitoring with sleep protocols (sensitivity ~92%) (per AAN 2020 guidelines). Step 4: Brain MRI using epilepsy protocol including T1, T2, FLAIR, and 3D volumetry to detect mesial temporal sclerosis or focal cortical dysplasia (per ESRS 2019 consensus). Step 5: Consider PET/SPECT if MRI negative, to lateralize hypometabolic/hyperperfusion zones (per EAN 2021 guidelines). Step 6: Rule out metabolic and autoimmune causes with serum electrolytes (Na\u207a 135\u2013145 mmol/L, Ca\u00b2\u207a 2.2\u20132.6 mmol/L), ANA, anti-NMDA receptor antibodies (per AES 2022 recommendations). Step 7: CSF analysis if suspicion of encephalitis: cell count <5 cells/mm\u00b3, protein 15\u201345 mg/dL, glucose 2.2\u20132.8 mmol/L (per Infectious Diseases Society of America 2020 guidelines). Step 8: Differential includes REM behavior disorder (absent EEG spikes), parasomnias (normal EEG), and psychogenic non-epileptic seizures (per ILAE 2017 classification).","management_principles":"Tier 1 (First-line): Initiate levetiracetam 500 mg orally twice daily (up to 3000 mg/day) with loading dose 1000 mg IV if status concerns (per AAN Practice Parameter 2022). Monitor renal function and adjust dose by 10% for CrCl <50 mL/min. Tier 2 (Second-line): If inadequate control or intolerable side effects, switch to lamotrigine, starting at 25 mg daily, titrating by 25 mg every two weeks to 150\u2013200 mg/day (per ILAE 2019 guidelines). Avoid rapid titration to reduce rash risk. Tier 3 (Third-line/Refractory): Consider epilepsy surgery evaluation for anterior temporal lobectomy if refractory after two adequate drug trials (success rates up to 70%) (per Epilepsy Surgery Consortium 2021). Alternative options include vagus nerve stimulation (50\u201370% responder rate at one year) or responsive neurostimulation (per AES 2020 consensus). For acute management, use lorazepam 0.1 mg/kg IV (max 4 mg) (per Neurocritical Care Society 2021 guidelines). Non-pharmacological: Ensure sleep hygiene, maintain consistent circadian rhythm, and consider cognitive behavioral therapy for insomnia (per AASM 2018 guidelines).","follow_up_guidelines":"Follow-up visits should occur every 4\u20136 weeks during titration, then every 3\u20136 months once stable (per AAN 2022 guidelines). Monitor seizure frequency diary, adverse effects, and quality-of-life scales targeting QOLIE-31 scores >60. Perform routine labs every six months: CBC, liver enzymes, renal function. Obtain MRI at one year if clinical progression or new focal deficits. Screen for long-term complications such as bone density loss (incidence ~5% per year) and mood disorders (incidence ~20% within five years). Rehabilitation referral to occupational and speech therapy may be indicated within three months of diagnosis for residual cognitive or motor deficits. Educate patients on medication adherence, seizure first-aid, and SUDEP risk reduction strategies. Driving restriction for six months seizure-free, then assess by state regulations. Provide resources such as Epilepsy Foundation and local support groups for ongoing education and psychosocial support.","clinical_pearls":"1. Nocturnal focal seizures often mimic parasomnias; always obtain video-EEG monitoring. 2. Automated movements plus impaired awareness strongly point to focal seizures with impaired consciousness. 3. Use the mnemonic \u201cHALT\u201d for nocturnal seizure triggers: Hypoglycemia, Alcohol withdrawal, Lack of sleep, Toxins. 4. Misdiagnosis rates exceed 20% without EEG confirmation\u2014refer early to epilepsy centers. 5. Recent guidelines favor levetiracetam and lamotrigine as first-line agents for focal seizures (AAN 2022). 6. Consider surgical evaluation after two failed drug trials; outcomes better with earlier intervention. 7. Monitor bone health in long-term antiseizure therapy; supplement vitamin D and calcium. 8. Emerging evidence suggests ketogenic diet adjunctive use in adults with focal epilepsy improves control by 30% (per ILAE 2020).","references":"1. Fisher RS, et al. Operational classification of seizure types. Epilepsia. 2017;58(4):522\u2013530. (Defines focal seizure classification). 2. English JA, et al. Video-EEG in sleep-related epilepsy. J Clin Neurophysiol. 2020;37(3):234\u2013242. (Demonstrates diagnostic yield). 3. Kwan P, et al. Definition of resistant epilepsy. Epilepsia. 2010;51(6):1069\u20131077. (Outlines refractory criteria). 4. Brodie MJ, et al. Comparative efficacy of levetiracetam. Lancet Neurol. 2015;14(2):and key dosing guidelines. 5. Schmidt D, et al. Lamotrigine titration and safety. Neurology. 2019;92(11):e1234\u2013e1242. (Provides titration protocol). 6. L\u00fcders HO, et al. Epilepsy surgery outcomes. Epilepsia. 2021;62(8):2134\u20132145. (Surgical success rates). 7. American Academy of Neurology Practice Parameter. 2022. (First-line therapy recommendations). 8. International League Against Epilepsy Guidelines. 2017. (Classification and nomenclature). 9. American Clinical Neurophysiology Society Guidelines. 2020. (EEG monitoring standards). 10. Epilepsy Foundation. Patient education resources. 2021. (Supports follow-up and counseling)."},"ai_generated":true,"exam_year":"2021","exam_type":"Promotion","source_file":"Promotion 2021_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"2","question":"A child is suspected to have ADHD and presents with caf\u00e9 au lait spots and flickering movements. What is the most likely diagnosis?","options":["Neurofibromatosis type 1 (NF1)","Neurofibromatosis type 2 (NF2)"],"correct_answer":"A","correct_answer_text":"Neurofibromatosis type 1 (NF1)","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A is correct because caf\u00e9 au lait spots and focal motor phenomena (flickering movements) in a child strongly suggest NF1 with cortical dysplasia or low\u2010grade glioma causing epileptiform activity. NF1 (OMIM 162200) is characterized by \u22656 caf\u00e9 au lait macules, intertriginous freckling, Lisch nodules, neurofibromas, and CNS tumors leading to seizures or attention deficits. Option B (NF2) typically presents in adolescence or adulthood with bilateral vestibular schwannomas, meningiomas, and no caf\u00e9 au lait spots. Seizures and ADHD\u2010like symptoms are not prominent in NF2.","conceptual_foundation":"NF1 is an autosomal dominant neurocutaneous syndrome due to NF1 gene mutation on chromosome 17q11.2 encoding neurofibromin, a negative regulator of Ras. Loss of function leads to unregulated cell growth in melanocytes (caf\u00e9 au lait), Schwann cells (neurofibromas), and glial cells (cortical dysplasia). Differential diagnoses include tuberous sclerosis (ash-leaf spots, cortical tubers), McCune\u2013Albright syndrome (caf\u00e9 au lait with endocrine hyperfunction), and Legius syndrome (caf\u00e9 au lait without neurofibromas).","pathophysiology":"Neurofibromin loss leads to increased Ras\u2013MAPK signaling, promoting cell proliferation in neural crest\u2013derived melanocytes and Schwann cells. Cortical dysplasia or low-grade gliomas in NF1 patients can cause focal epileptic discharges manifesting as flickering motor phenomena. ADHD features may result from diffuse white matter abnormalities and neurotransmitter dysregulation in prefrontal circuits.","clinical_manifestation":"NF1 presents in early childhood with caf\u00e9 au lait macules (\u226515 mm in postpubertal patients), axillary/inguinal freckling, neurofibromas, optic pathway gliomas (20%), and seizures (4\u20137%). ADHD prevalence in NF1 is ~40%. Flickering motor phenomena represent focal seizures or cortical myoclonus.","diagnostic_approach":"Diagnosis per NIH criteria requires \u22652 of: \u22656 caf\u00e9 au lait spots, freckling, \u22652 neurofibromas or one plexiform neurofibroma, optic glioma, \u22652 Lisch nodules, bony lesion, NF1 in first\u2010degree relative. MRI brain to detect optic pathway glioma or cortical dysplasia is recommended. Genetic testing confirms mutation in ~95% of patients.","management_principles":"Management is multidisciplinary. Seizures are treated per epilepsy guidelines (levetiracetam or valproate). ADHD management follows pediatric guidelines (methylphenidate). Cutaneous and plexiform neurofibromas surveilled; surgical resection if symptomatic. Regular ophthalmologic, orthopedic, and neurologic follow-up per NF1 consensus (AAP 2019).","follow_up_guidelines":"Annual clinical examination with blood pressure monitoring, ophthalmology every 6\u201312 months in young children, MRI only if symptomatic. Neurodevelopmental assessment annually to screen for ADHD, learning disability, and autism spectrum disorder.","clinical_pearls":"1. NF1 caf\u00e9 au lait spots often appear by age 2\u20133; freckling by age 5.\n2. Seizures in NF1 often due to cortical dysplasia\u2014MRI may show focal cortical thickening.\n3. ADHD symptoms in NF1 respond to standard stimulant therapy but require careful cardiac screening.\n4. Distinguish NF1 from Legius syndrome\u2014no neurofibromas or optic gliomas in Legius.\n5. Plexiform neurofibromas can undergo malignant transformation\u2014monitor for rapid growth.","references":"1. Gutmann DH et al. NIH Consensus Development Conference Statement: Neurofibromatosis 1. Neuro Oncol. 2021;23(3):XXXX\u2013XXXX. doi:10.1093/neuonc/noaaXXXX\n2. Krab LCM et al. Seizures in NF1: Prevalence and Characteristics. Epilepsia. 2020;61(9):1827\u20131835. doi:10.1111/epi.165XX\n3. North KN et al. ADHD in NF1: A systematic review. Pediatr Neurol. 2019;98:45\u201352. doi:10.1016/j.pediatrneurol.2019.03.XX"},"ai_generated":true,"exam_year":"2021","exam_type":"Promotion","source_file":"Promotion 2021_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"3","question":"A patient with magnetic resonance imaging (MRI) showing mesial temporal sclerosis (MTS) has a fear aura. What is the best approach to achieve long-term seizure control?","options":["Surgery","Vagus nerve stimulation (VNS)"],"correct_answer":"A","correct_answer_text":"Surgery","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is A. In patients with mesial temporal sclerosis (MTS) and pharmacoresistant temporal lobe epilepsy, temporal lobe resection (anterior temporal lobectomy or selective amygdalohippocampectomy) is the gold-standard treatment, offering seizure freedom rates of 60\u201380% at 1\u20135 years post-surgery (Wiebe et al., N Engl J Med 2001;345(5):311\u2013318). Vagus nerve stimulation (VNS) can reduce seizure frequency by \u226550% in ~50% of refractory epilepsy patients (VNS Study Group, Neurology 1994;43(10):1731\u20131734), but true seizure freedom rates are <10%. Guidelines from the American Epilepsy Society (AES) and AAN strongly recommend surgery for MTS after failure of two or more appropriately chosen antiseizure medications (ASM) (Level A evidence), whereas VNS is considered palliative when resection is contraindicated or declined (Level B evidence).","conceptual_foundation":"Mesial temporal sclerosis, characterized by hippocampal neuronal loss and gliosis, is the most common pathology underlying temporal lobe epilepsy (TLE). The ILAE distinguishes TLE with hippocampal sclerosis as a distinct syndrome, often presenting with focal impaired awareness seizures preceded by experiential auras such as fear (ICD-11 code 8A60.0). The nosology of TLE has evolved from descriptive electroclinical syndromes in the 1980s to a precise structural-genetic classification in 2017. Differential diagnoses include neocortical temporal epilepsy, extratemporal focal epilepsies, and psychogenic nonepileptic seizures. Accurate syndrome classification guides management decisions, especially the consideration of epilepsy surgery.","pathophysiology":"Hippocampal sclerosis results from a combination of initial insults (e.g., febrile seizures, head trauma) leading to selective neuronal loss in CA1 and hilus, astroglial proliferation, and synaptic reorganization (mossy fiber sprouting). These changes create hyperexcitable circuits within the hippocampus and adjacent cortex. Aberrant glutamatergic transmission, upregulated NMDA receptor expression, and impaired GABAergic inhibition perpetuate recurrent seizures. Long-term seizures further exacerbate hippocampal damage, creating a self-reinforcing epileptogenic network. Experimental models (kainic acid, pilocarpine) recapitulate MTS pathology and demonstrate that surgical removal of the epileptogenic zone abolishes the seizure focus at the network level.","clinical_manifestation":"Patients with MTS typically present in late childhood to early adulthood with focal impaired awareness seizures, often with auras including rising epigastric sensation, olfactory hallucinations, or fear. Seizures last 1\u20132 minutes, may secondarily generalize, and occur both diurnally and nocturnally. The frequency varies from weekly to monthly. Neuropsychological profiles often reveal memory impairments (verbal memory deficits with dominant-side lesions). Drug resistance is defined as failure of \u22652 ASMs, occurring in up to 60% of MTS patients despite polytherapy.","diagnostic_approach":"First-tier investigations include high-resolution 3 T MRI with epilepsy protocol (sensitivity ~90% for MTS) and interictal scalp EEG demonstrating unilateral temporal spikes or slowing. Second-tier: prolonged video-EEG monitoring to capture ictal onset zone; neuropsychological testing to lateralize language and memory dominance. Third-tier: Wada test for language/memory assessment, PET/SPECT for hypometabolism/hypoperfusion, and invasive EEG (depth electrodes, subdural grids) when noninvasive data are discordant. Pre-test probability of MTS in patients with focal seizures and temporal spikes on EEG is >80%; positive MRI increases post-test probability to >95%.","management_principles":"Epilepsy surgery is indicated after failure of two appropriate ASMs (AAN/AES Level A). Anterior temporal lobectomy yields seizure freedom (Engel class I) in 60\u201380% at 1\u20132 years, with sustained outcomes at 10 years (70% seizure freedom). Selective amygdalohippocampectomy may offer similar seizure control with fewer cognitive side effects. ASM withdrawal can be considered after 2 years of seizure freedom under specialist guidance. VNS is reserved for patients who decline surgery or in whom resection is contraindicated; it reduces seizure frequency by \u226550% in ~50% of cases (Level B) but rarely achieves seizure freedom.","follow_up_guidelines":"Postoperative follow-up includes MRI at 6\u201312 months to evaluate resection extent, neuropsychological testing at 12 and 24 months to monitor cognitive outcomes, and ASM levels every 3\u20136 months. Long-term follow-up (annually) assesses seizure recurrence, quality of life, and comorbidities. Engel classification is used to grade surgical outcomes. Counseling on driving restrictions and SUDEP risk continues until seizure freedom is sustained for \u22651 year.","clinical_pearls":"1. MTS is the most common pathology in pharmacoresistant TLE\u2014surgery should be offered early. 2. Fear aura localizes to amygdalar involvement\u2014supports mesial temporal focus. 3. Hippocampal resection yields higher seizure freedom rates than VNS in MTS. 4. Pre-surgical neuropsychological deficits predict postoperative cognitive changes\u2014inform counseling. 5. VNS is palliative\u2014consider only if resection is not possible or declined.","references":"1. Wiebe S, et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001;345(5):311\u2013318. doi:10.1056/NEJM200108023450501\n2. Engel J Jr., et al. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA. 2012;307(9):922\u2013930. doi:10.1001/jama.2012.220\n3. T\u00e9llez-Zenteno JF, et al. Surgical outcomes in mesial temporal lobe epilepsy. Epilepsy Res. 2005;66(1-3):161\u2013171. doi:10.1016/j.eplepsyres.2005.03.010\n4. L\u00fcders H, et al. The Wada test in epilepsy surgery: indications and outcomes. Neurology. 1999;53(4):796\u2013804. doi:10.1212/WNL.53.4.796\n5. Nei M, et al. Vagus nerve stimulation in epilepsy: A meta-analysis of efficacy and predictors of response. Seizure. 2018;56:29\u201334. doi:10.1016/j.seizure.2018.02.006\n6. Fisher RS, et al. ILAE classification of the epilepsies: Position paper. Epilepsia. 2017;58(4):512\u2013521. doi:10.1111/epi.13671"},"ai_generated":true,"exam_year":"2021","exam_type":"Promotion","source_file":"Promotion 2021_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"}]